Reduced or modified dietary fat for preventing cardiovascular disease

Abstract

Background Reduction and modification of dietary fats have differing effects on cardiovascular risk factors (such as serum cholesterol), but their effects on important health outcomes are less clear. Objectives To assess the effect of reduction and/or modification of dietary fats on mortality, cardiovascular mortality, cardiovascular morbidity and individual outcomes including myocardial infarction, stroke and cancer diagnoses in randomised clinical trials of at least 6 months duration. Search methods For this review update, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE, were searched through to June 2010. References of Included studies and reviews were also checked. Selection criteria Trials fulfilled the following criteria: 1) randomised with appropriate control group, 2) intention to reduce or modify fat or cholesterol intake (excluding exclusively omega-3 fat interventions), 3) not multi factorial, 4) adult humans with or without cardiovascular disease, 5) intervention at least six months, 6) mortality or cardiovascular morbidity data available. Data collection and analysis Participant numbers experiencing health outcomes in each arm were extracted independently in duplicate and random effects meta-analyses, meta-regression, sub-grouping, sensitivity analyses and funnel plots were performed. Main results This updated review suggested that reducing saturated fat by reducing and/or modifying dietary fat reduced the risk of cardiovascular events by 14% (RR 0.86, 95% CI 0.77 to 0.96, 24 comparisons, 65,508 participants of whom 7% had a cardiovascular event, I2 50%). Subgrouping suggested that this reduction in cardiovascular events was seen in studies of fat modification (not reduction - which related directly to the degree of effect on serum total and LDL cholesterol and triglycerides), of at least two years duration and in studies of men (not of women). There were no clear effects of dietary fat changes on total mortality (RR 0.98, 95% CI 0.93 to 1.04, 71,790 participants) or cardiovascular mortality (RR 0.94, 95% CI 0.85 to 1.04, 65,978 participants). This did not alter with sub-grouping or sensitivity analysis. Few studies compared reduced with modified fat diets, so direct comparison was not possible. Authors’ conclusions The findings are suggestive of a small but potentially important reduction in cardiovascular risk on modification of dietary fat, but not reduction of total fat, in longer trials. Lifestyle advice to all those at risk of cardiovascular disease and to lower risk population groups, should continue to include permanent reduction of dietary saturated fat and partial replacement by unsaturates. The ideal type of unsaturated fat is unclear.

Dietary fat guidelines have no evidence base: where next for public health nutritional advice?

“…The other two significant findings were related to cardiovascular disease (CVD) events and not mortality 50 55. In 2011, including RCTs with a minimum of 6 months duration, Hooper et al found 1 significant result and 11 non-significant results.…”

Nutritional Challenges and Opportunities during the Weaning Period and in Young Childhood

“…levels <10 en% and preferably lower [1,18], are recommended to reduce the long-term risk of heart disease [18]. Even at a young age, high dietary intakes of SFA have been shown to increase plasma total and LDL cholesterol concentrations and could enhance vascular lipid deposition and the occurrence of early vascular lesions [57,58,59,60]. In the Special Turku Coronary Risk Factor Intervention Project (STRIP), 1,000 healthy infants were randomized to a low-saturated-fat, low-cholesterol diet counseling group and a control group and were followed every 6-12 months throughout childhood.…”

The Effect of High-Dose Simvastatin Therapy on Patients with Acute Cerebral Infarction

“…Cerebrovascular disease (CVD) is the third most common cause of death worldwide [1,2]. CVD accounts for the major cause of morbidity and mortality in industrialized countries and responsible for stroke and transient ischemic attack (TIA) [3,4].…”